Using advanced cardiac imaging to predict strokes in patients without atrial fibrillation

Advanced Cardiac Imaging To Predict Embolic Stroke On Brain MRI: A Pilot Study

Not applicable Interventional Tulane University · NCT04769310

This study is testing if advanced heart imaging can help predict strokes in people who don't have atrial fibrillation by looking for specific signs in their hearts.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment120 (estimated)
Ages18 Years to 120 Years
SexAll
SponsorTulane University Academic / other
Locations1 site (New Orleans, Louisiana)
Trial IDNCT04769310 on ClinicalTrials.gov

What this trial studies

This study aims to establish a connection between left atrial and left atrial appendage pathology and the occurrence of embolic strokes in individuals who do not have a history of atrial fibrillation. It will involve a cross-sectional cohort of patients with specific risk factors, who will undergo cardiac magnetic resonance imaging (CMR) and brain MRI to identify potential markers of stroke risk. The study will analyze the relationship between cardiac imaging features and the presence of embolic strokes on brain MRI, potentially leading to improved stroke prevention strategies. By identifying high-risk individuals based on imaging criteria, the study seeks to inform future anticoagulation strategies for stroke prevention beyond atrial fibrillation.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with a CHA2DS2VASC score of 3 or higher and a history of type II diabetes or congestive heart failure, but no history of atrial fibrillation.

Not a fit: Patients with a history of atrial fibrillation or those who have had a recent symptomatic stroke within the last 30 days may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to better identification of patients at risk for embolic strokes, allowing for targeted prevention strategies.

How similar studies have performed: While this approach is innovative, similar studies have shown promise in using imaging to assess stroke risk, indicating potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or female patients
* 18 Years and older
* No history of atrial fibrillation
* CHA2DS2VASC score ≥3
* History pf type II diabetes
* History of congestive heart failure or a history of transient ischemic attack (TIA)/stroke without an otherwise defined stroke etiology such as large vessel or small vessel disease

Exclusion Criteria:

* History of atrial fibrillation
* Patients who had a clinically symptomatic acute stroke within the last 30-days
* Any health-related gadolinium/MRI contraindication (including previous allergic reaction to Gadolinium, pacemakers, defibrillators, other devices/implants contraindicated for MRI)
* Estimated glomerular filtration rate (eGFR) cutoff in patients with Chronic kidney disease (CKD) where gadolinium cannot be used equals an eGFR \<30 ml/min
* Weighing \> 300 lbs (as CMR image quality decreases due to increased body mass index)
* Current pregnancy or breastfeeding
* Cognitive impairment preventing the patient from giving an informed consent

Where this trial is running

New Orleans, Louisiana

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Atrial FibrillationStrokeStroke, CardiovascularVascular Cognitive ImpairmentStrokes ThromboticStroke, IschemicMagnetic Resonance ImagingCardiac Magnetic Resonance Imaging
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.